Neoadjuvant therapy for resectable mucosal melanoma
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs (SHR-1701 and famitinib) before surgery to shrink mucosal melanoma, followed by additional treatment based on how the tumor responds. It aims to improve outcomes for patients with this rare type of melanoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with mucosal melanoma (melanoma that starts in moist areas like the mouth, nose, or digestive tract).
- Your melanoma is considered completely removable by surgery, with or without limited spread to nearby lymph nodes or a few other spots.
- You are in good physical condition (able to carry out daily activities, ECOG score 0 or 1).
- You have not previously been treated with PD-1/PD-L1 inhibitors (a type of immunotherapy) or anti-angiogenic drugs (which block blood vessel growth).
- You do not have a history of bleeding problems or abnormal blood clotting, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs, AK104 or AK112, combined with a targeted therapy called axitinib for people with metastatic mucosal melanoma (a rare type of skin cancer that has spread). The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This trial tests whether giving a combination of three immunotherapy drugs before surgery can help shrink melanoma and improve outcomes. It is for people whose melanoma can be surgically removed, and the goal is to see if this approach is safe and effective.
This trial tests a new drug called PRJ1-3024 for people with advanced melanoma that has not responded to standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests a combination of chemo drugs (paclitaxel polymersomes, carboplatin) and an immunotherapy (adebelimab) before surgery for people with mucosal melanoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests two drugs given before surgery to shrink melanoma that has spread to lymph nodes. The goal is to see if this combination helps remove the cancer more effectively.
This trial tests whether two medications, lenvatinib (a targeted therapy) and pembrolizumab (an immunotherapy), given before and after surgery, can help reduce the chance of mucosal melanoma coming back. If you are eligible, you would receive these drugs in addition to your standard surgery.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.